[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 9, 2002

Cost-effectiveness of Homocysteine-Lowering Therapy to Prevent Coronary Heart Disease

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(2):190-192. doi:10.1001/jama.287.2.186

To the Editor: In their cost-effectiveness analysis of vitamin supplementation to lower homocysteine levels and prevent coronary heart disease, Dr Tice and colleagues1 did not use data from beyond February 1999. The modeling in Table 1 of their article is actually not needed, since 2 controlled total homocysteine (tHcy)–lowering treatment studies have been conducted in the United States and Canada among patients with coronary artery disease who have been chronically exposed to a background of folic acid–fortified cereal grain flour since 1999.2,3 These studies show that tHcy-lowering effects are only one third to one half of those listed by Tice et al.

First Page Preview View Large
First page PDF preview
First page PDF preview
×